Questions were designed by a core group of multi-disciplinary HCPs, validated by the UKMRA EDI group and distributed through the UK Myeloma Society (UKMS) and the British Oncology Pharmacy Association (BOPA). H
Article Open access Published: 21 December 2022 Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma Andrea Keppler-Hafkemeyer, Christine Greil, Paul R. Wratil, Khalid Shoumariyeh, Marcel Stern,...
1. Giralt S: Treatment conundrums in myeloma. 2022 Community Oncology Alliance’s Community Oncology Conference. Presented March 17, 2022. 2. Usmani SZ, Hoering A, Cavo M, et al: Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma: An IMWG research...
To understand the extent of the problem, Pfizer’s Didem Aydin, MD, PhD, global medical director of multiple myeloma, recently co-authoreda systemic reviewof global health disparities among MM patients.6Multiple studies included in the review found that Black individuals are more likely than white...
Despite the significant advances in the treatment of multiple myeloma (MM), this disease is still considered incurable because of relapse and chemotherapy resistance, underscoring the need to seek novel therapies with different mechanisms. Anlotinib, a n
29, 30, 31 Ixazomib is approved in the United States and European Union in combination with Rd for the treatment of multiple myeloma (MM) patients who have received ≥1 prior therapy.32, 33, 34 Ixazomib-Rd has also been investigated in early-phase trials in NDMM patients, demonstrating ...
Clinical trialsLymphomaHematologyMultiple myeloma (MM) is the second most common hematological malignancy with an incidence of 4.3 per 100,000 in the general population, and a median survival of 3–5 years ( 1 ). It is a malignancy of the plasma cells, usually immature plasmablasts that ...
Multiple Myeloma By Matthew Stenger / July 2024 Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong ...
The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
Multiple myeloma (MM) remains a challenging hematologic malignancy despite advancements in chimeric antigen receptor T-cell (CAR-T) therapy. Current targets of CAR-T cells used in MM immunotherapy have limitations, with a subset of patients experiencing antigen loss resulting in relapse. Therefore, ...